Shukra Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Shukra Pharmaceuticals Ltd trades at ₹41.4, in a confirmed uptrend and 34 weeks into that stage. That is +16.8% against its own 200-day average. It sits at 62% of a 52-week range of ₹12 to ₹59. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is in a confirmed uptrend — week 34 of stage 2, confirmed. At ₹41.4 it trades +16.8% versus its 200-day average and sits at 62% of its 52-week range (₹12–₹59).

Against the market, two honest reads. Cumulative: over the last 10.0 years the stock moved +15,835% while the NIFTY 500 moved +260% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 80th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Shukra Pharmaceuticals Ltd trades at 62.2× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 31.0×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 62.2× is at the pricey end of its own range (80th percentile), against a long-run median of 31.0× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −47.6% against a +75.3% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 10y, of the +66.0%/yr price move, ~+52.3%/yr came from earnings growth and ~+13.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Shukra Pharmaceuticals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

64.5/100 — rank 2 of 10 in Pharma - Others · 66% evidence confidence

Shukra Pharmaceuticals Ltd scores 64.5 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 21.8 + 16.8 + 9.3 + 16.6 = 64.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Shukra Pharmaceuticals Ltd reported ₹39.0 Cr of revenue in the Dec 25 quarter, +254.5% year on year. Over 10 years it has compounded at 27.1% a year. The last full year, FY25, came in at ₹33.0 Cr. The last four reported quarters add to ₹63.0 Cr.

Shukra Pharmaceuticals Ltd reported ₹39.0 Cr of revenue in the Dec 25 quarter, +254.5% year on year. Over 10 years it has compounded at 27.1% a year. The last full year, FY25, came in at ₹33.0 Cr. The last four reported quarters add to ₹63.0 Cr.

FY25 revenue came in at ₹33.0 Cr (−56.0% on the year), capping 10 years at 27.1% compound. The latest quarter (Dec 25) printed ₹39.0 Cr, +254.5% year on year.

Pace check: the last four quarters averaged +84.8% growth against the decade's 27.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +103.2% over the last 4 quarters against −24.3%/yr over the last 8 — accelerating; TTM profit +250.0% vs +24.7%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 69.0% this quarter (+32.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Shukra Pharmaceuticals Ltd's operating margin is 69.0% in the Dec 25 quarter, +32.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged −10.0% to 39.0%. The current quarter is running above every full year in that window.

Shukra Pharmaceuticals Ltd's operating margin is 69.0% in the Dec 25 quarter, +32.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged −10.0% to 39.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 69.0%, +32.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −10.0%–39.0%, and FY25's 39.0% is the top of that band — a record year.

Why the margin moved: operating margin went +32.2 pp year on year while gross margin went +19.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins held — did that reach the bottom line? Next: profit +566.7% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Shukra Pharmaceuticals Ltd earned ₹20.0 Cr of net profit in the Dec 25 quarter, +566.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was ₹10.0 Cr. That is 51.3% of the quarter's revenue. The same quarter a year earlier earned ₹3.0 Cr.

Shukra Pharmaceuticals Ltd earned ₹20.0 Cr of net profit in the Dec 25 quarter, +566.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was ₹10.0 Cr. That is 51.3% of the quarter's revenue. The same quarter a year earlier earned ₹3.0 Cr.

Dec 25 profit was ₹20.0 Cr, +566.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed ₹10.0 Cr (−47.4%).

Why profit moved: revenue contributed +254.5% and the margin +32.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +230.6% vs revenue +84.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 18% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 18% of Shukra Pharmaceuticals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY25 that was ₹8.0 Cr of operating cash against ₹10.0 Cr of profit. After ₹2.0 Cr of capital spending, ₹6.0 Cr was left as free cash.

FY25: operating cash of ₹8.0 Cr against reported profit of ₹10.0 Cr, leaving free cash of ₹6.0 Cr after ₹2.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 18% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 18%: the cash cycle stretched 503 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 503 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 131-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Shukra Pharmaceuticals Ltd's cash conversion cycle runs 131 days in FY25, up from −372 days in FY20. Capital spending ran ₹8.0 Cr over the last 3 years. At FY25 sales of ₹33.0 Cr each day of that cycle holds about ₹0.1 Cr, so roughly ₹12.0 Cr sits inside the business at any moment.

FY25: debtors at 98 days, inventory at 447 days — roughly 14.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 131 days, looser than FY20's −372.

The full loop: cash goes out to suppliers and production on day 0; stock waits 447 days to sell; customers pay about 98 days after that; and suppliers themselves are paid at 414 days — netting out to the 131-day cycle.

In money terms: at FY25 sales of ₹33.0 Cr, each day of the cycle holds about ₹0.1 Cr — so the 131-day loop keeps roughly ₹12.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹8.0 Cr over the last 3 fiscal years against ₹7.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY25) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 22%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Shukra Pharmaceuticals Ltd earns a ROCE of 22% in FY25. That is up from a trough of −6% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 30.3% net margin on 0.38× asset turns.

FY25 ROCE is 22%, recovered from a FY14 trough of −6% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 30.3% net margin × 0.38× asset turns × 1.38× balance-sheet leverage ≈ 15.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.06.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Shukra Pharmaceuticals Ltd carries ₹4.0 Cr of borrowings against ₹63.0 Cr of equity in FY25, a debt-to-equity of 0.06. Operating profit covers the interest bill 13×. Over 5 years borrowings went from ₹8.0 Cr to ₹4.0 Cr. Capital spending ran ₹8.0 Cr across the last 3 of those years.

FY25: borrowings of ₹4.0 Cr against equity of ₹63.0 Cr — a debt-to-equity of 0.06. Operating profit covers the interest bill 13×. Over 5 years borrowings went from ₹8.0 Cr to ₹4.0 Cr while capital spending ran ₹8.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Shukra Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.0 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +0.0 points over 8 quarters to 51.0%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Shukra Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions